• View Press Releases

    View Press Releases

News & Media

Recent News

Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma More

Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting More

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma More

View All News

Quick Facts

Year founded 1998

Nasdaq SGEN

Number of Employees 1,000+

Global Headquarters Bothell, WA

European Headquarters Zug, Switzerland


Primary Product ADCETRIS® (brentuximab vedotin)


Disease Focus Areas Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, breast cancer, acute myeloid leukemia


Clinical & preclinical pipeline programs 12+

ADCs in clinical trials using our technology 20+


Social Media


Media Contacts

For Media Professionals Only

Brandi Robinson

Sr. VP, Corporate Communications